Panelists discuss how the updated SEQUOIA Arm C data demonstrate that zanubrutinib monotherapy achieves a remarkable 72% ...

Katherine McDaniel, MD, discusses the barriers to fertility preservation access for patients diagnosed with cancer.

Panelists discuss how real-world evidence studies from databases like Flatiron demonstrate that second-generation Bruton ...

The oral casein kinase 1α and cyclin dependent kinase 7/9 inhibitor BTX A51 revealed a manageable safety profile in relapsed ...

Panelists discuss how the treatment landscape for treatment-naive patients with chronic lymphocytic leukemia (CLL) is rapidly ...

Katherine McDaniel, MD, a reproductive endocrinologist, discusses the key takeaways for oncologists treating patients of reproductive age.

An expert discusses emerging real-world strategies for managing adverse effects of antibody-drug conjugates (ADCs) in ...

The FDA has cleared investigational new drug applications for ZW251 and RV‑01, advancing novel treatments for solid tumors in first-in-human trials.

Panelists discuss how future directions in chronic lymphocytic leukemia (CLL) treatment include promising developments with Bruton tyrosine kinase (BTK) degraders, noncovalent BTK inhibitors, ...

Panelists discuss how measurable residual disease (MRD) testing should be used primarily for prognostic information rather than routine treatment decision-making, with current guidelines recommending ...

Atezolizumab enhances long-term outcomes in triple-negative breast cancer, revealing promising insights on ctDNA as a prognostic biomarker.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...